Prof. Univ. Dr. Calin Cainap

• 2013: 23rd Melanoma Preceptorship Meeting: Sentinel Node Biopsy and Adjuvant Treatment Department Of Dermatology, University of Kiel, Germany
• 2006 - 2010: Doctor in Stiinte Medicale - Rolul Chimioterapiei adjuvante de generatie a treia in managementul cancerului gastric operat radical, Universitatea de Medicina si Farmacie "Iuliu Hatieganu", Cluj Napoca
• 2002: Attestation Formation Specialisee D’oncologie, University of Medicine And Pharmacy,
  Rouen, France
• 2002 - 2003: Attestation Formation Specialisee D’oncologie, Faculte de Medicine, Paris Sud, France (Institut Gustave Roussy Villejuif)
• 1991 - 1997: Facultatea de Medicina Generala, Universitatea de Medicina si Farmacie "Iuliu Hatieganu", Cluj-Napoca

• 2009: Advanced Training Course In Hcc Management Division Of Gastroenterology And Hepatology Medizinische Universitat Wien

Distinctii onorifice si premii:

• 2021: Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1 PRECISI-2021-62799
• 2021: Partnering bevacizumab with irinotecan as first-line therapy of metastatic colorectal cancer improves progression free-survival A retrospective study – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1-PRECISI-2021 63156
• 2021: Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center. – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1-PRECISI-2021-63159
• 2021: Diagnostic Performance of F18-FDG PET/CT in Male Breast Cancers Patients – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1- PRECISI-2021-56788
• 2021: A Comparative Study between 18F-FDG PET/CT and Conventional Imaging in the Evaluation of Progressive Disease and Recurrence in Ovarian Carcinoma – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1-PRECISI-2021 57285
• 2021: Next Generation Sequencing Technology in Lung Cancer Diagnosis – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2021 PN-III-P1-1.1- PRECISI-2021-64803
• 2020: Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2020 PN-III-P1-1.1-PRECISI-2020-45353
• 2020: Left Supraclavicular Lymph Node Metastasis from Ovarian Cancer Associated with Papillary Thyroid Microcarcinoma, a Confusing Pathology-Essential Role of Functional Imaging – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2020 PN-III-P1-1.1-PRECISI-2020-45695
• 2020: Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2020 PN-III-P1-1.1-PRECISI-2020-51924 2020 Early diagnosis and screening in lung cancer. – Competitia UEFISCDI PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2020 PN-III-P1-1.1-PRECISI-2020-51363
• 2019: The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2019 PN-III-P1-1.1- PRECISI-2019- 35124
• 2015: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2015 PN-II-RU-PRECISI-2015-9-8187
• 2015: Conformational landscape and low lying excited states of imatinib. J Mol Model. 2015 Apr;21(4):84 – UEFISCDI- PREMIEREA REZULTATELOR CERCETARII – ARTICOLE Competitia PRECISI 2015 PN-II-RU- PRECISI-2015-9-9198

• 2022: Influenza A, Influenza B, and SARS-CoV-2 similarities and differences – a focus on diagnosis
• 2022: Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers
• 2022: Next Generation Sequencing Technology in Lung Cancer Diagnosis
• 2021: Predictive Efficacy of MiR-125b-5p, MiR-17-5p, and MiR-185-5p in Liver Metastasis and Chemotherapy Response Among Advanced Stage Colorectal Cancer Patients
• 2021: Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center.
• 2020: Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in an ovarian cancer
  case: A case report.
• 2020: Early diagnosis and screening in lung cancer.
• 2020: Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT
• 2020: Treatment beyond progression in metastatic colorectal cancer: to double or not to double the dose of bevacizumab?
• 2020: Exosomal miRNAs in colorectal cancer: the carriers of useful news
• 2020: Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
• 2019: Interleukin 8 as predictive factor for response to chemotherapy in colorectal cancer patients
• 2019: The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type KRAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
• 2018: The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children
  treated for leukemia.
• 2018: The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases.
• 2017: Platinum derivatives: a multidisciplinary approach
• 2016: Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with
  radically resected gastric cancer.
• 2016: Chemotherapy – induced cardiotoxicity in oncology drugs involved and clinical assessment
• 2015: Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a
  randomized phase III trial.
• 2015: Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? Reply to M. Bouattour et al.
• 2015: Hypersensitivity reactions to platinum derivatives: findings of new predictive markers
• 2015: The prognostic role of EBER in pediatric cancer 
• 2010: New generation chemotherapy in the treatment of operated gastric cancer--an alternative to
  traditional chemotherapy
• 2005: Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.